PAN 90806

Drug Profile

PAN 90806

Alternative Names: CP-547,632; CP-632; OSI-632; PAN90806

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OSI Pharmaceuticals; Pfizer
  • Developer PanOptica; Pfizer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Wet age-related macular degeneration
  • Phase I Diabetic retinopathy
  • Discontinued Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 06 Oct 2017 PanOptica plans a phase I/II trial with the next-generation formulation for Wet age-related macular degeneration in early 2018
  • 14 Oct 2016 Efficacy and adverse events data from a phase I/II trial in Wet age-related macular degeneration released by PanOptica
  • 01 Aug 2015 Phase-I clinical trials in Diabetic retinopathy in USA (Ophthalmic) (NCT02475109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top